The CR rate was consistent across subgroups including men and women, patients with and without papillary disease, and ...

Dr. Kazuyuki Numakura presented a study of primary resistance to nivolumab + ipilimumab therapy affecting second-line treatment outcomes in metastatic renal cell carcinoma (mRCC) patients. Long-term ...

Oncologists at AUA 2025 share promising data, including sasanlimab, cretostimogene grenadenorepvec, and TAR-200 in NMIBC.

With an FDA review underway, Johnson & Johnson is aiming to “fundamentally change” how bladder cancer is treated. | With an ...

The SOPHIA study retrospectively investigated the first-in-man safety and efficacy in 6 patients with stress urinary incontinence who received the UroActive TM device. Results from the primary ...

A new study published in the International Journal of Urology showed that patients with muscle-invasive bladder cancer (MIBC) ...

Data to be presented in Clinical Trials in Progress Session on Monday, April 28, 2025CORAL GABLES, Fla., April 27, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the ...

Under the National Quality Assurance Standards (NWAS) currently there are 30,000 Ayushman Arogya Mandirs and the government's ...

Joseph Jacob, MD, discusses data from the phase 2b SunRISe-1 study, cohort 2, evaluating TAR-200 in BCG-unresponsive high-risk NMIBC with carcinoma in situ.